Global Beta-Thal Disease Market Research Report 2022
Global Beta-Thal Disease Market Overview:
Global Beta-Thal Disease Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Beta-Thal Disease involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Beta-Thal Disease Market
The Beta-Thal Disease Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Beta-Thal Disease Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Beta-Thal Disease Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Beta-Thal Disease Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Beta-Thal Disease market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Beta-Thal Disease Market Segmentation
Global Beta-Thal Disease Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Beta-Thal Disease market has been segmented into:
Iron Chelating Drugs
Gene Therapy
By Application, Beta-Thal Disease market has been segmented into:
Hospitals
Biotechnological Laboratories
Diagnostic Laboratories
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Beta-Thal Disease market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Beta-Thal Disease market.
Top Key Players Covered in Beta-Thal Disease market are:
Acceleron Pharma
Inc.
Incyte Corporation
La Jolla Pharmaceutical Company
bluebird bio
Inc.
Celgene Corporation
Gamida Cell
IONIS Pharmaceuticals
GlaxoSmithKline plc
Kiadis Pharma
Objective to buy this Report:
1. Beta-Thal Disease analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Beta-Thal Disease market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Global Beta-Thal Disease Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Beta-Thal Disease involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Beta-Thal Disease Market
The Beta-Thal Disease Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Beta-Thal Disease Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Beta-Thal Disease Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Beta-Thal Disease Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Beta-Thal Disease market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Beta-Thal Disease Market Segmentation
Global Beta-Thal Disease Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Beta-Thal Disease market has been segmented into:
Iron Chelating Drugs
Gene Therapy
By Application, Beta-Thal Disease market has been segmented into:
Hospitals
Biotechnological Laboratories
Diagnostic Laboratories
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Beta-Thal Disease market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Beta-Thal Disease market.
Top Key Players Covered in Beta-Thal Disease market are:
Acceleron Pharma
Inc.
Incyte Corporation
La Jolla Pharmaceutical Company
bluebird bio
Inc.
Celgene Corporation
Gamida Cell
IONIS Pharmaceuticals
GlaxoSmithKline plc
Kiadis Pharma
Objective to buy this Report:
1. Beta-Thal Disease analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Beta-Thal Disease market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
CHAPTER 1: INTRODUCTION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: BETA-THAL DISEASE MARKET BY TYPE
5.1 BETA-THAL DISEASE MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 BETA-THAL DISEASE MARKET OVERVIEW
5.3 IRON CHELATING DRUGS
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 IRON CHELATING DRUGS: GEOGRAPHIC SEGMENTATION
5.4 GENE THERAPY
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 GENE THERAPY: GEOGRAPHIC SEGMENTATION
CHAPTER 6: BETA-THAL DISEASE MARKET BY APPLICATION
6.1 BETA-THAL DISEASE MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 BETA-THAL DISEASE MARKET OVERVIEW
6.3 HOSPITALS
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 HOSPITALS: GEOGRAPHIC SEGMENTATION
6.4 BIOTECHNOLOGICAL LABORATORIES
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 BIOTECHNOLOGICAL LABORATORIES: GEOGRAPHIC SEGMENTATION
6.5 DIAGNOSTIC LABORATORIES
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 DIAGNOSTIC LABORATORIES: GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 BETA-THAL DISEASE SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 BETA-THAL DISEASE INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 BETA-THAL DISEASE PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 ACCELERON PHARMA
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 INC.
7.4 INCYTE CORPORATION
7.5 LA JOLLA PHARMACEUTICAL COMPANY
7.6 BLUEBIRD BIO
7.7 INC.
7.8 CELGENE CORPORATION
7.9 GAMIDA CELL
7.10 IONIS PHARMACEUTICALS
7.11 GLAXOSMITHKLINE PLC
7.12 KIADIS PHARMA
CHAPTER 8: GLOBAL BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 IRON CHELATING DRUGS
8.2.2 GENE THERAPY
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 HOSPITALS
8.3.2 BIOTECHNOLOGICAL LABORATORIES
8.3.3 DIAGNOSTIC LABORATORIES
CHAPTER 9: NORTH AMERICA BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 IRON CHELATING DRUGS
9.4.2 GENE THERAPY
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 HOSPITALS
9.5.2 BIOTECHNOLOGICAL LABORATORIES
9.5.3 DIAGNOSTIC LABORATORIES
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 IRON CHELATING DRUGS
10.4.2 GENE THERAPY
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 HOSPITALS
10.5.2 BIOTECHNOLOGICAL LABORATORIES
10.5.3 DIAGNOSTIC LABORATORIES
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 IRON CHELATING DRUGS
11.4.2 GENE THERAPY
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 HOSPITALS
11.5.2 BIOTECHNOLOGICAL LABORATORIES
11.5.3 DIAGNOSTIC LABORATORIES
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 IRON CHELATING DRUGS
12.4.2 GENE THERAPY
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 HOSPITALS
12.5.2 BIOTECHNOLOGICAL LABORATORIES
12.5.3 DIAGNOSTIC LABORATORIES
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 IRON CHELATING DRUGS
13.4.2 GENE THERAPY
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 HOSPITALS
13.5.2 BIOTECHNOLOGICAL LABORATORIES
13.5.3 DIAGNOSTIC LABORATORIES
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: BETA-THAL DISEASE MARKET BY TYPE
5.1 BETA-THAL DISEASE MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 BETA-THAL DISEASE MARKET OVERVIEW
5.3 IRON CHELATING DRUGS
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 IRON CHELATING DRUGS: GEOGRAPHIC SEGMENTATION
5.4 GENE THERAPY
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 GENE THERAPY: GEOGRAPHIC SEGMENTATION
CHAPTER 6: BETA-THAL DISEASE MARKET BY APPLICATION
6.1 BETA-THAL DISEASE MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 BETA-THAL DISEASE MARKET OVERVIEW
6.3 HOSPITALS
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 HOSPITALS: GEOGRAPHIC SEGMENTATION
6.4 BIOTECHNOLOGICAL LABORATORIES
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 BIOTECHNOLOGICAL LABORATORIES: GEOGRAPHIC SEGMENTATION
6.5 DIAGNOSTIC LABORATORIES
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 DIAGNOSTIC LABORATORIES: GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 BETA-THAL DISEASE SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 BETA-THAL DISEASE INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 BETA-THAL DISEASE PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 ACCELERON PHARMA
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 INC.
7.4 INCYTE CORPORATION
7.5 LA JOLLA PHARMACEUTICAL COMPANY
7.6 BLUEBIRD BIO
7.7 INC.
7.8 CELGENE CORPORATION
7.9 GAMIDA CELL
7.10 IONIS PHARMACEUTICALS
7.11 GLAXOSMITHKLINE PLC
7.12 KIADIS PHARMA
CHAPTER 8: GLOBAL BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 IRON CHELATING DRUGS
8.2.2 GENE THERAPY
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 HOSPITALS
8.3.2 BIOTECHNOLOGICAL LABORATORIES
8.3.3 DIAGNOSTIC LABORATORIES
CHAPTER 9: NORTH AMERICA BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 IRON CHELATING DRUGS
9.4.2 GENE THERAPY
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 HOSPITALS
9.5.2 BIOTECHNOLOGICAL LABORATORIES
9.5.3 DIAGNOSTIC LABORATORIES
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 IRON CHELATING DRUGS
10.4.2 GENE THERAPY
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 HOSPITALS
10.5.2 BIOTECHNOLOGICAL LABORATORIES
10.5.3 DIAGNOSTIC LABORATORIES
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 IRON CHELATING DRUGS
11.4.2 GENE THERAPY
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 HOSPITALS
11.5.2 BIOTECHNOLOGICAL LABORATORIES
11.5.3 DIAGNOSTIC LABORATORIES
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 IRON CHELATING DRUGS
12.4.2 GENE THERAPY
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 HOSPITALS
12.5.2 BIOTECHNOLOGICAL LABORATORIES
12.5.3 DIAGNOSTIC LABORATORIES
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA BETA-THAL DISEASE MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 IRON CHELATING DRUGS
13.4.2 GENE THERAPY
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 HOSPITALS
13.5.2 BIOTECHNOLOGICAL LABORATORIES
13.5.3 DIAGNOSTIC LABORATORIES
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BETA-THAL DISEASE MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BETA-THAL DISEASE MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BETA-THAL DISEASE MARKET COMPETITIVE RIVALRY
TABLE 005. BETA-THAL DISEASE MARKET THREAT OF NEW ENTRANTS
TABLE 006. BETA-THAL DISEASE MARKET THREAT OF SUBSTITUTES
TABLE 007. BETA-THAL DISEASE MARKET BY TYPE
TABLE 008. IRON CHELATING DRUGS MARKET OVERVIEW (2016-2028)
TABLE 009. GENE THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. BETA-THAL DISEASE MARKET BY APPLICATION
TABLE 011. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 012. BIOTECHNOLOGICAL LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 013. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 016. N BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 019. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 022. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 025. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 028. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 029. ACCELERON PHARMA: SNAPSHOT
TABLE 030. ACCELERON PHARMA: BUSINESS PERFORMANCE
TABLE 031. ACCELERON PHARMA: PRODUCT PORTFOLIO
TABLE 032. ACCELERON PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. INC.: SNAPSHOT
TABLE 033. INC.: BUSINESS PERFORMANCE
TABLE 034. INC.: PRODUCT PORTFOLIO
TABLE 035. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. INCYTE CORPORATION: SNAPSHOT
TABLE 036. INCYTE CORPORATION: BUSINESS PERFORMANCE
TABLE 037. INCYTE CORPORATION: PRODUCT PORTFOLIO
TABLE 038. INCYTE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. LA JOLLA PHARMACEUTICAL COMPANY: SNAPSHOT
TABLE 039. LA JOLLA PHARMACEUTICAL COMPANY: BUSINESS PERFORMANCE
TABLE 040. LA JOLLA PHARMACEUTICAL COMPANY: PRODUCT PORTFOLIO
TABLE 041. LA JOLLA PHARMACEUTICAL COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. BLUEBIRD BIO: SNAPSHOT
TABLE 042. BLUEBIRD BIO: BUSINESS PERFORMANCE
TABLE 043. BLUEBIRD BIO: PRODUCT PORTFOLIO
TABLE 044. BLUEBIRD BIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. INC.: SNAPSHOT
TABLE 045. INC.: BUSINESS PERFORMANCE
TABLE 046. INC.: PRODUCT PORTFOLIO
TABLE 047. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. CELGENE CORPORATION: SNAPSHOT
TABLE 048. CELGENE CORPORATION: BUSINESS PERFORMANCE
TABLE 049. CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 050. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. GAMIDA CELL: SNAPSHOT
TABLE 051. GAMIDA CELL: BUSINESS PERFORMANCE
TABLE 052. GAMIDA CELL: PRODUCT PORTFOLIO
TABLE 053. GAMIDA CELL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. IONIS PHARMACEUTICALS: SNAPSHOT
TABLE 054. IONIS PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 055. IONIS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 056. IONIS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 057. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 058. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 059. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. KIADIS PHARMA: SNAPSHOT
TABLE 060. KIADIS PHARMA: BUSINESS PERFORMANCE
TABLE 061. KIADIS PHARMA: PRODUCT PORTFOLIO
TABLE 062. KIADIS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BETA-THAL DISEASE MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BETA-THAL DISEASE MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BETA-THAL DISEASE MARKET COMPETITIVE RIVALRY
TABLE 005. BETA-THAL DISEASE MARKET THREAT OF NEW ENTRANTS
TABLE 006. BETA-THAL DISEASE MARKET THREAT OF SUBSTITUTES
TABLE 007. BETA-THAL DISEASE MARKET BY TYPE
TABLE 008. IRON CHELATING DRUGS MARKET OVERVIEW (2016-2028)
TABLE 009. GENE THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. BETA-THAL DISEASE MARKET BY APPLICATION
TABLE 011. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 012. BIOTECHNOLOGICAL LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 013. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 016. N BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 019. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 022. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 025. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA BETA-THAL DISEASE MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA BETA-THAL DISEASE MARKET, BY APPLICATION (2016-2028)
TABLE 028. BETA-THAL DISEASE MARKET, BY COUNTRY (2016-2028)
TABLE 029. ACCELERON PHARMA: SNAPSHOT
TABLE 030. ACCELERON PHARMA: BUSINESS PERFORMANCE
TABLE 031. ACCELERON PHARMA: PRODUCT PORTFOLIO
TABLE 032. ACCELERON PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. INC.: SNAPSHOT
TABLE 033. INC.: BUSINESS PERFORMANCE
TABLE 034. INC.: PRODUCT PORTFOLIO
TABLE 035. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. INCYTE CORPORATION: SNAPSHOT
TABLE 036. INCYTE CORPORATION: BUSINESS PERFORMANCE
TABLE 037. INCYTE CORPORATION: PRODUCT PORTFOLIO
TABLE 038. INCYTE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. LA JOLLA PHARMACEUTICAL COMPANY: SNAPSHOT
TABLE 039. LA JOLLA PHARMACEUTICAL COMPANY: BUSINESS PERFORMANCE
TABLE 040. LA JOLLA PHARMACEUTICAL COMPANY: PRODUCT PORTFOLIO
TABLE 041. LA JOLLA PHARMACEUTICAL COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. BLUEBIRD BIO: SNAPSHOT
TABLE 042. BLUEBIRD BIO: BUSINESS PERFORMANCE
TABLE 043. BLUEBIRD BIO: PRODUCT PORTFOLIO
TABLE 044. BLUEBIRD BIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. INC.: SNAPSHOT
TABLE 045. INC.: BUSINESS PERFORMANCE
TABLE 046. INC.: PRODUCT PORTFOLIO
TABLE 047. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. CELGENE CORPORATION: SNAPSHOT
TABLE 048. CELGENE CORPORATION: BUSINESS PERFORMANCE
TABLE 049. CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 050. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. GAMIDA CELL: SNAPSHOT
TABLE 051. GAMIDA CELL: BUSINESS PERFORMANCE
TABLE 052. GAMIDA CELL: PRODUCT PORTFOLIO
TABLE 053. GAMIDA CELL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. IONIS PHARMACEUTICALS: SNAPSHOT
TABLE 054. IONIS PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 055. IONIS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 056. IONIS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 057. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 058. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 059. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. KIADIS PHARMA: SNAPSHOT
TABLE 060. KIADIS PHARMA: BUSINESS PERFORMANCE
TABLE 061. KIADIS PHARMA: PRODUCT PORTFOLIO
TABLE 062. KIADIS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BETA-THAL DISEASE MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BETA-THAL DISEASE MARKET OVERVIEW BY TYPE
FIGURE 012. IRON CHELATING DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 013. GENE THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. BETA-THAL DISEASE MARKET OVERVIEW BY APPLICATION
FIGURE 015. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 016. BIOTECHNOLOGICAL LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 017. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BETA-THAL DISEASE MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BETA-THAL DISEASE MARKET OVERVIEW BY TYPE
FIGURE 012. IRON CHELATING DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 013. GENE THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. BETA-THAL DISEASE MARKET OVERVIEW BY APPLICATION
FIGURE 015. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 016. BIOTECHNOLOGICAL LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 017. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA BETA-THAL DISEASE MARKET OVERVIEW BY COUNTRY (2016-2028)
